Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy+Abiraterone/Prednisone and Androgen Deprivation Therapy+Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer
- Author:
Dong Jin PARK
1
;
Tae Gyun KWON
;
Jae Young PARK
;
Jae Young JOUNG
;
Hong Koo HA
;
Seong Soo JEON
;
Sung-Hoo HONG
;
Sungchan PARK
;
Seung Hwan LEE
;
Jin Seon CHO
;
Sung-Woo PARK
;
Se Yun KWON
;
Jung Ki JO
;
Hong Seok PARK
;
Sang-Cheol LEE
;
Dong Deuk KWON
;
Sun Il KIM
;
Sang Hyun PARK
;
Soodong KIM
;
Chang Wook JEONG
;
Cheol KWAK
;
Seock Hwan CHOI
;
Author Information
- Publication Type:Original Article
- From:The World Journal of Men's Health 2024;42(3):620-629
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:This study aimed to compare the short-term outcomes and safety profiles of androgen-deprivation therapy (ADT)+abiraterone/prednisone with those of ADT+docetaxel in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC).
Materials and Methods:A web-based database system was established to collect prospective cohort data for patients with mHSPC in Korea. From May 2019 to November 2022, 928 patients with mHSPC from 15 institutions were enrolled. Among these patients, data from 122 patients who received ADT+abiraterone/prednisone or ADT+docetaxel as the primary systemic treatment for mHSPC were collected. The patients were divided into two groups: ADT+abiraterone/prednisone group (n=102) and ADT+docetaxel group (n=20). We compared the demographic characteristics, medical histories, baseline cancer status, initial laboratory tests, metastatic burden, oncological outcomes for mHSPC, progression after mHSPC treatment, adverse effects, follow-up, and survival data between the two groups.
Results:No significant differences in the demographic characteristics, medical histories, metastatic burden, and baseline cancer status were observed between the two groups. The ADT+abiraterone/prednisone group had a lower prostate-specific antigen (PSA) progression rate (7.8% vs. 30.0%; p=0.011) and lower systemic treatment discontinuation rate (22.5% vs. 45.0%; p=0.037). No significant differences in adverse effects, oncological outcomes, and total follow-up period were observed between the two groups.
Conclusions:ADT+abiraterone/prednisone had lower PSA progression and systemic treatment discontinuation rates than ADT+docetaxel. In conclusion, further studies involving larger, double-blinded randomized trials with extended follow-up periods are necessary.
